Drug intelligence / Profile preview

RG013

Development stage: Preclinical
Lead developer: Rigerna Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RG013 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Rigerna Bio. It utilizes a kidney-targeted delivery platform to achieve gene knockdown of an undisclosed target for the treatment of metabolic and renal diseases. As of early 2024, the program is in the Preclinical Candidate (PCC) stage of development, focusing on localized delivery to the kidneys to improve therapeutic efficacy and reduce systemic side effects.

Beyond the preview

Go deeper on RG013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG013.

Explore the full profile